Back to today’s briefing

Story perspectives

Markets Soar Amid Rate Cut; Kenvue Faces Controversy

9/23/2025

47 5 Full Breakdown

Summary

Markets Surge Amid Fed Cuts

September 23, 2025: Dow and S&P 500 hit record highs; Nasdaq slid.
The Federal Reserve's rate cut boosted optimism, but officials caution about inflation.
Kenvue's stock fell after reports linking Tylenol use in pregnancy to autism.
Trump administration proposed a $100,000 H-1B visa fee, raising concerns among tech firms.
Pfizer to acquire Metsera for $4.9 billion to boost weight-loss drugs.

Summary

Investors React to Fed

Sept. 23, 2025: gold prices rise past $3,800/oz as investors anticipate Fed rate cuts.
Wall Street mixed: Dow up 0.3%, S&P 500 flat, Nasdaq -0.1%.
Nvidia shares fall 1.3% after a surge tied to its OpenAI partnership, impacting performance; Fed Chair Jerome Powell's speech is awaited.
Kenvue up 5.6% as Tylenol autism concerns ease; Trump's cautions offer no new evidence.

History

Historical Context

The 2008 financial crisis prompted the Federal Reserve to cut interest rates from 5.25% to nearly zero by December 2008, expanding its balance sheet to $2.1 trillion by 2009 to stimulate the economy. Today, as the Fed's rate cuts boost market optimism, inflation concerns echo historical challenges, reflecting the ongoing tension between economic growth and price stability.

1 of 3

Markets Surge Amid Fed Cuts

September 23, 2025: Dow and S&P 500 hit record highs; Nasdaq slid.
The Federal Reserve's rate cut boosted optimism, but officials caution about inflation.
Kenvue's stock fell after reports linking Tylenol use in pregnancy to autism.
Trump administration proposed a $100,000 H-1B visa fee, raising concerns among tech firms.
Pfizer to acquire Metsera for $4.9 billion to boost weight-loss drugs.

1 / 3